---
title: "RenovoRx files late notice for 2024 annual report"
url: "https://aibio.space/news/renovorx-files-late-notice-2024-annual-report-cites-auditor-accounting/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-03-31"
section: "Distress"
tickers: "NASDAQ:RNXT"
source: "https://www.sec.gov/Archives/edgar/data/1574094/000164117225001842/formnt10-k.htm"
summary: "RenovoRx said it needs to complete technical accounting requirements with its current and former auditing firms. It expects to file within the fifteen-day"
---

By the aibio.space news desk.

Sources

- [RenovoRx, Inc. NT 10-K (2025-03-31)](https://www.sec.gov/Archives/edgar/data/1574094/000164117225001842/formnt10-k.htm)

[RNXT](https://aibio.space/companies/renovorx/)

2025-03-31

# RenovoRx files late notice for 2024 annual report, cites auditor accounting work

Tickers [RNXT](https://aibio.space/companies/renovorx/)

RenovoRx said it needs to complete technical accounting requirements with its current and former auditing firms. It expects to file within the fifteen-day grace period.

## Key facts

- **Company**: RenovoRx, Inc. (NASDAQ: RNXT)

- **News type**: Distress

- **Primary source**: [RenovoRx, Inc. NT 10-K (2025-03-31)](https://www.sec.gov/Archives/edgar/data/1574094/000164117225001842/formnt10-k.htm)

*A columned courthouse. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.*

RenovoRx, Inc. said on March 31, 2025, that it cannot file its Form 10-K for the year ended December 31, 2024, within the prescribed time.

The Mountain View, California company filed a Form 12b-25, a notification of late filing. The form gives a company a short automatic extension when it cannot meet a deadline. For an annual report, the extension is fifteen days.

RenovoRx said it could not file without unreasonable effort or expense "because of the need to complete certain technical accounting requirements with the Registrant's current and former auditing firms." It expects to file the 10-K within the fifteen-day grace period provided by Rule 12b-25.

The company said it has filed all other periodic reports required during the preceding 12 months.

It also previewed its results without giving figures. RenovoRx expects to recognize small initial revenue from its RenovoCath commercial efforts for 2024, compared with 2023. It also expects a small decrease in net loss, due in part to lower selling, general and administrative expenses. The company said these amounts are still under review by its independent registered public accounting firm and accounting staff and may differ once reported.

The full text is in RenovoRx's [Form NT 10-K](https://www.sec.gov/Archives/edgar/data/1574094/000164117225001842/formnt10-k.htm).

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

RNXT

RenovoRx, Inc.

NASDAQ · United States

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/renovorx-files-late-notice-2024-annual-report-cites-auditor-accounting/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "RenovoRx files late notice for 2024 annual report", 2025-03-31, https://aibio.space/news/renovorx-files-late-notice-2024-annual-report-cites-auditor-accounting/